<DOC>
	<DOCNO>NCT01055301</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Biological therapy , thalidomide lenalidomide , may stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , dexamethasone , cisplatin , doxorubicin hydrochloride , cyclophosphamide , etoposide , melphalan , work different way stop growth cancer cell , either kill cell stop dividing . Combining chemotherapy autologous stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . Giving bortezomib , thalidomide , combination chemotherapy transplant lenalidomide transplant may effective treatment multiple myeloma . PURPOSE : This phase II trial study well give bortezomib , thalidomide , lenalidomide together combination chemotherapy autologous stem cell transplant work treat patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>S0833 , Bortezomib , Thalidomide , Lenalidomide , Combination Chemotherapy , Autologous Stem Cell Transplant Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess progression-free survival ( PFS ) 3 year patient newly diagnose multiple myeloma ( MM ) treat modified Total Therapy 3 ( TT3 ) . Secondary - To estimate frequency severity toxicity associate treatment strategy patient . Correlative - To perform gene expression profile CD138+ purify MM cell unseparated bone marrow biopsy sample identify bone marrow micro-environment signature . - To determine whether 70-gene model , develop Arkansas Total Therapy 2 ( TT2 ) validate Arkansas TT3 study , also apply cooperative group set . - Determine whether novel find TT3 prognostically favorable suppression micro-environment-associated gene , MAG1 , also apply cooperative group set . - Once complete remission , determine whether MAG signatures return normal individual 's signature indication profound tumor cytoreduction durable PFS . OUTLINE : This multicenter study . - Induction therapy : Patients receive bortezomib IV day 1 , 4 , 8 , 11 ; oral thalidomide oral dexamethasone day 1-4 ; cisplatin IV continuously , doxorubicin hydrochloride IV continuously , cyclophosphamide IV continuously , etoposide IV continuously day 1-4 . - Peripheral blood stem cell ( PBSC ) collection : Beginning within 2 month completion induction therapy , patient undergo PBSC collection adequate number cell collect . Patients persistent disease completion induction therapy proceed bridge therapy adequate stem cell collect . Patients require bridge therapy proceed directly transplant . - Bridging therapy : Patients receive oral thalidomide day 1-21 oral dexamethasone day 1 , 8 , 15 . Treatment repeat every 21 day 1-2 course absence disease progression unacceptable toxicity . Patients proceed transplant . - First autologous PBSC transplantation : Beginning within 6 week 3 month completion induction therapy ( ≥ 1 week completion bridge therapy ) , patient receive bortezomib IV day -4 -1 melphalan IV , oral thalidomide , oral dexamethasone day -4 -1 . Patients undergo autologous PBSC transplantation day 0 . - Inter-transplant bridging therapy : Patients persistent disease completion first autologous PBSC transplant receive bridge therapy proceed second transplant . Patients require bridge therapy proceed directly second transplant . - Second autologous PBSC transplantation : Beginning within 6 month first PBSC transplant , patient receive bortezomib , melphalan , thalidomide , dexamethasone undergo autologous PBSC first transplant . Patients skip second transplant ( due medical insurance reason refusal ) proceed consolidation therapy . - Consolidation therapy : Beginning within 6 month last transplant , patient receive bortezomib , thalidomide , dexamethasone , cisplatin , doxorubicin hydrochloride , cyclophosphamide , etoposide induction therapy . - Post-consolidation bridging therapy : Patients persistent disease completion consolidation therapy receive oral thalidomide day 1-21 oral dexamethasone day 1 , 8 , 15 . Patients proceed maintenance therapy . Patients require bridge therapy proceed directly maintenance therapy . - Maintenance therapy : Beginning within 4 month completion consolidation therapy post-consolidation bridging therapy , patient receive bortezomib IV oral dexamethasone day 1 , 8 , 15 , 22 oral lenalidomide day 1-20 . Courses repeat every 28 day 3 year absence disease progression unacceptable toxicity . Blood bone marrow sample may collect baseline periodically study gene expression profile analysis . After completion study therapy , patient follow periodically 7 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose active multiple myeloma ( MM ) Measurable disease Nonsecretory disease allow provided patient ≥ 20 % plasmacytosis multiple ( &gt; 3 ) focal plasmacytoma skeletal survey and/or MRI PATIENT CHARACTERISTICS : Zubrod performance status ( PS ) 02 ( Zubrod PS 34 allow base solely bone pain ) ANC ≥ 1,500/mm^3* Platelet count ≥ 150,000/mm^3* Serum creatinine clearance ≥ 60 mL/min Patients creatinine clearance &lt; 60 mL/min receive low dose melphalan No patient receive plan receive dialysis Total bilirubin ≤ 1.5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must fully aware teratogenic potential thalidomide Must willing comply FDAmandated S.T.E.P.S . program Ejection fraction &gt; 40 % measure MUGA scan twodimensional ECHO No peripheral neuropathy ≥ grade 2 per CTCAE v. 4.0 No know hypersensitivity bortezomib , boron , mannitol No uncontrolled diabetes define fast glucose level &gt; 200 mg/dL least two occasion two serum random blood level &gt; 300 mg/dL despite adequate treatment Patients history diabetes mellitus require treatment stable regimen blood glucose closely monitor No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient receive treatment within past year NOTE : *Unless myelomarelated marrow infiltration document , define ≥ 30 % marrow cellularity 50 % cell malignant plasma cell . PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy radiotherapy No 1 prior course chemotherapy MM Prior chemotherapy must include melphalan No prior radiotherapy large area pelvis ( half pelvis ) Prior radiotherapy symptomatic localize bone lesion impend cord compression allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>